STOCK TITAN

Gyre Therapeutics, Inc. (GYRE) Net Income by Year

GYRE

Gyre Therapeutics, Inc. reported $9.9M in net income in fiscal year 2025. This represents a decrease of 44.8% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $25.7M net loss. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Gyre Therapeutics, Inc. has filed alongside them.

FY2025 annual
Net Income $9.9M
YoY -44.8%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

GYRE Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
Net Income-$25.7M$9.9M-44.8%$17.9M+120.9%-$85.5M-2081.5%$4.3M+104.9%-$87.9M-56.4%-$56.2M-1.9%-$55.2M-83.6%-$30.1M-39.4%-$21.6M-27.2%-$16.9M-14.8%-$14.8M-123.2%-$6.6M+33.6%-$10.0M-42.4%-$7.0M+18.0%-$8.5M

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

GYRE Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$14.3M-537.9%-$18.6M-476.2%$1.2M+118.3%$5.9M+107.8%-$2.2M-149.3%$4.9M-50.3%$569K+100.6%$2.9M-62.0%$4.5M+20.4%$9.9M+135.6%-$101.0M$7.5M+253.8%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Gyre Therapeutics, Inc. financials

Frequently Asked Questions

What was Gyre Therapeutics, Inc.'s net income in fiscal year 2025?

Gyre Therapeutics, Inc. reported $9.9M in net income in fiscal year 2025.

How fast is Gyre Therapeutics, Inc.'s net income growing?

Gyre Therapeutics, Inc. (GYRE) net income fell by 44.8% year over year, from $17.9M to $9.9M in fiscal year 2025.

What is Gyre Therapeutics, Inc.'s net income over the last twelve months?

Gyre Therapeutics, Inc. (GYRE) reported a $25.7M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 15 fiscal years this page covers, Gyre Therapeutics, Inc. (GYRE) net income went from -$8.5M in fiscal year 2011 to $9.9M in fiscal year 2025.

Gyre Therapeutics, Inc. (GYRE) reported -$14.3M in net income in Q2 2026. This represents a decrease of 537.9% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Gyre Therapeutics, Inc. (GYRE) reported on that line in every period on record.